Young patients who went on a clinical trial for a new medication to treat severe, chronic hand eczema have reported “life-changing” results, prompting dermatologists in Walsall to encourage more to come forward to take part.

The Manor Hospital was the first site in Europe to offer the DELTA Teen study to those aged 12-17 who suffer from this condition which can be debilitating for sufferers and severely limit their daily lives.

Dr James Halpern, Consultant Dermatologist at Walsall Healthcare NHS Trust, said: “We have seen our first participants come to the end of the trial and we are working with them to evaluate the results and fully capture their outcomes – but it is fair to say that it has been “life-changing.”

“This severe condition can have a significant impact on the lives of those affected and this is felt in so many areas of their lives. It can be extremely limiting which not only prevents may of the activities that others take for granted but has mental health consequences too. We have been so proud to be able to offer this trial in Walsall and, based on this initial success, want to encourage others who may be eligible to take part to come forward to be considered.”

Patients may qualify for this clinical trial if they are between 12 and 17, have had moderate to severe hand eczema for at least three months and if previous treatment with steroid cream has been unsuccessful or is unsuitable for them.

This clinical trial will last for up to 22 weeks and participants will apply trial medication twice a day for 16 weeks during this time. There will be eight visits to the trial clinic and one phone call with the trial staff.

There is no cost to take part in this clinical trial and reasonable travel costs will be reimbursed.

For more details, or to be considered for this study, contact Walsall.research1@nhs.net